Graduated in Management Engineering, in the company since 2013, he becomes director of the Bu dedicated to the therapeutic area that the Japanese pharmaceutical industry has been leading for almost thirty years
by Aboutpharma Online editorial staff
June 7, 2021
Stefano Sommella is the new director of Takeda Italia’s gastrointestinal therapeutic area business unit. The company announces it in a note. With a degree in Management Engineering, he began his career as a Business Analyst at Accenture, later joining the pharmaceutical sector at Pfizer, where he held roles of increasing responsibility in the marketing & sales sector. He joined Takeda in 2013 as Pharmacy channel franchise manager, later promoted to Market access strategy lead. He was also Commercial Operations Director and Integration Leader, a key role in Shire’s acquisition and operational integration process.
Commitment against Crohn’s disease and ulcerative colitis
“With a wide range of therapies for gastrointestinal diseases, such as the first ‘gut-selective’ biotech drug for ulcerative colitis and Crohn’s disease – comments Sommella – Takeda demonstrates not only market leadership, but also continuous commitment to patient well-being. This new responsibility of mine, in one of the therapeutic areas of excellence for the company, will see me committed to promoting the search for innovative solutions and therapies starting from listening to the real needs of patients. A challenge that excites me ”.
Projects and awards
Sommella achieved the Takeda Eucan (Europe & Canada Business Unit) President’s Award in 2020, a recognition for his dedication and constant commitment.
Under his direction, Takeda Italia has carried out two telemedicine projects: “10 for 10” – a home remote assistance project for Covid-19 patients carried out together with the Lazio Region and the Lazzaro Spallanzani hospital – and ‘Smart homes’, created in Oliveto Citra, in the province of Salerno, with the aim of solving the problem of advanced home care for lonely and frail people.
Towards new results
“Gastroenterology represents for Takeda a key sector for business and for the generation of value for patients – adds Annarita Egidi, CEO of Takeda Italy – With almost 30 years of experience in this therapeutic area, the company continues to reach new achievements in the development of innovative treatments and solutions, making use of cutting-edge technologies. We expect from Stefano a further leap forward: experience, enthusiasm and energy are his characteristics that we put to work to achieve important results for our patients and – concludes the CEO – for the growth of Takeda Italia ”.